Kalyan Roy: Rediscovering Cold-Stored Platelets in Modern Transfusion Medicine
Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:
“Cold-Stored Platelets (CSP): A Rediscovered Tool in Modern Transfusion Medicine
Cold-stored platelets are gaining renewed attention as a targeted option for treating active bleeding, especially in trauma and surgical settings.
A brief history
Before the 1960s, platelets were naturally transfused cold within refrigerated whole blood.
In 1969, research showed cold-stored platelets had shorter post-transfusion survival, leading to the shift toward room-temperature (RT) platelet storage, which remains the standard today.
Why the renewed interest?
- CSP show stronger early clot formation and may resist fibrinolysis better than RT platelets.
- In bleeding patients, rapid hemostasis matters more than long circulation time.
- Early clinical studies (trauma, surgery, cardiopulmonary bypass) suggest similar bleeding outcomes and transfusion needs, supporting potential non-inferiority.
Operational advantages
- Longer shelf life – up to ~14 days vs ~5 days for RT platelets.
- Lower bacterial growth risk due to cold storage (1–6°C).
- No agitation or bacterial mitigation required, simplifying storage logistics.
Manufacturing updates
- Produced in platelet additive solution (PAS) to reduce aggregates.
- Pathogen reduction (PR) removes need for irradiation and CMV-negative units.
- Lower rates of allergic reactions and minimal risk of hemolysis.
Current regulatory guidance
The FDA recommends CSP primarily for active bleeding when conventional platelets are unavailable or impractical. Hospitals are encouraged to define institution-specific protocols for use.
What’s next?
Large trials such as CHIPS, CriSP-HS, and CriSP-TBI are underway to better define the role of CSP in trauma, hemorrhagic shock, and cardiac surgery.
Bottom line:
Cold-stored platelets are not a replacement for standard platelet inventory—but they may become a valuable targeted therapy for rapid bleeding control, especially when logistics or availability are challenging.
Discussion:
Is your institution exploring CSP implementation or dual platelet inventory strategies?”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis